An impressive 77% of those diagnosed are now surviving beyond 12 months, with only one NHS trust surpassing this achievement.

“Broadening access to cladribine means thousands more patients will benefit from managing their treatment at home rather than regularly attending hospital appointments – as well giving women with MS ...